PLUS1
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| AnaptysBio Inc | ANAB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.01 | -0.09% | 10.99 | 11.48 | 10.6205 | 11.00 | 11.00 | 11:20:29 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 10.99 | 11.02 | 0.03 | 0.27% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,905 | 531,053 | $ 10.99 | $ 5,836,357 | 895,630 | 9.16 - 83.10 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:20:29 | 3 | $ 10.99 | USD |
AnaptysBio Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 297.25M | 27.05M | $ -61.66M | -2.50 | - | 26.64M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
AnaptysBio News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/08/2019 | 08:09 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 11/08/2019 | 08:06 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/08/2019 | 08:05 | GlobeNewswire Inc. | AnaptysBio Announces Third Quarter 2019 Financial Results.. |
| 11/08/2019 | 08:00 | GlobeNewswire Inc. | AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in.. |
| 9/30/2019 | 16:19 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 9/30/2019 | 16:15 | GlobeNewswire Inc. | AnaptysBio Reports Positive Topline Data from Interim.. |
| 9/27/2019 | 06:30 | GlobeNewswire Inc. | AnaptysBio to Present at the Cantor Fitzgerald Global.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ANAB Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 37.88 | 38.51 | 9.16 | 10.56 | 5,694,402 | -26.89 | -70.99% |
| 1 Month | 36.50 | 39.48 | 9.16 | 13.18 | 1,575,030 | -25.51 | -69.89% |
| 3 Months | 43.26 | 46.34 | 9.16 | 20.66 | 750,225 | -32.27 | -74.6% |
| 6 Months | 72.47 | 79.09 | 9.16 | 32.06 | 502,614 | -61.48 | -84.84% |
| 1 Year | 70.75 | 83.10 | 9.16 | 44.45 | 389,389 | -59.76 | -84.47% |
| 3 Years | 16.00 | 134.00 | 9.16 | 61.99 | 328,971 | -5.01 | -31.31% |
| 5 Years | 16.00 | 134.00 | 9.16 | 61.99 | 328,971 | -5.01 | -31.31% |
AnaptysBio Description
| AnaptysBio Inc is a US-based clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. |
